openPR Logo
Press release

Deadline on Sept 27th upcoming in Lawsuit for Investors in Oasmia Pharmaceutical AB (publ) (NASDAQ: OASM)

09-10-2019 05:46 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A Deadline is coming up on September 27, 2019 in the lawsuit for certain investors in Oasmia Pharmaceutical AB (publ).

A Deadline is coming up on September 27, 2019 in the lawsuit for certain investors in Oasmia Pharmaceutical AB (publ).

The Shareholders Foundation announced that a deadline is coming up on September 27, 2019 in the lawsuit filed for certain investors of Oasmia Pharmaceutical AB (publ) (NASDAQ: OASM) over alleged securities laws violations by Oasmia Pharmaceutical AB (publ).

Investors who purchased shares of Oasmia Pharmaceutical AB (publ) (NASDAQ: OASM) have certain options and there are strict and short deadlines running. Deadline: September 27, 2019. NASDAQ: OASM stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

According to the complaint filed in the U.S. District Court for the Eastern District of New York the plaintiff alleges on behalf of purchasers of Oasmia Pharmaceutical AB (publ) (NASDAQ: OASM) common shares between October 23, 2015 through July 9, 2019, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between October 23, 2015 through July 9, 2019, the defendants made false and/or misleading statements and/or failed to disclose that Oasmia engaged in improper related-party transactions with Alceco International S.A. and Ardenia Investment LTD, which were controlled by Defendant Aleksov and his former father-in-law, that due to those transactions, millions of Swedish kronor were not accounted for in Oasmia's books;, that transactions concerning Oasmia's patents were also "carried out in a doubtful way;" and that as a result of the aforementioned misconduct, defendants' statements about Oasmia's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

Those who purchased shares of Oasmia Pharmaceutical AB (publ) (NASDAQ: OASM) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Deadline on Sept 27th upcoming in Lawsuit for Investors in Oasmia Pharmaceutical AB (publ) (NASDAQ: OASM) here

News-ID: 1831690 • Views: 357

More Releases from Shareholders Foundation

Investigation announced for Long-Term Investors in shares of Hecla Mining Compan …
An investigation was announced for investors in shares of Hecla Mining Company (NYSE: HL) concerning potential breaches of fiduciary duties by certain directors and officers of Hecla Mining Company. Investors who are current long term investors in Hecla Mining Company (NYSE: HL) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors
Investigation announced for Investors in Sasol Limited (NYSE: SSL) shares over p …
Sasol Limited is under investigation over potential securities laws violations in connection with certain financial statements. Investors who purchased shares of Sasol Limited (NYSE: SSL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Sasol Limited (NYSE: SSL regarding its business, its prospects and its operations were materially false and
Lawsuit filed for Investors in shares of MacroGenics, Inc. (NASDAQ: MGNX)
An investor, who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX), filed a lawsuit over alleged violations of Federal Securities Laws by MacroGenics, Inc.. Investors who purchased shares of MacroGenics, Inc. (NASDAQ: MGNX) have certain options and for certain investors are short and strict deadlines running. Deadline: November 12, 2019. NASDAQ: MGNX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. Rockvillem MD based MacroGenics, Inc., a biopharmaceutical
Investigation announced for Investors in shares of The RealReal, Inc. (NASDAQ: R …
An investigation was announced concerning potential securities laws violations by The RealReal, Inc. in connection with certain financial statements was announced. Investors who purchased shares of The RealReal, Inc. (NASDAQ: REAL), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by The RealReal, Inc. regarding its business, its prospects and its

All 5 Releases


More Releases for Oasmia

What's driving the Pet Cancer Therapeutics Market trends? prominent players |Zoe …
What's driving the Pet Cancer Therapeutics Market trends? prominent players |Zoetis, Merial, Aratana Therapeutics, AB Science, Vetivax, Oasmia Pharmaceutical, VetDC, Regeneus, CanFel Therapeutics, Karyopharms Verdinexor. U.S. pet cancer therapeutics market is the biggest cash cow for pharmaceutical companies. Early adopting nature of the country will attract companies to introduce their offerings first in the U.S.; augmenting the market growth. Pet Cancer Therapeutics Market to exceed USD 320 million by 2024.Increase in
Pet Cancer Therapeutics Market Growing at a CAGR of 10% to 2024 | Top Key Player …
Market Study Report LLC adds Global Pet Cancer Therapeutics market report that gives meticulous investigation of current scenario of the market size, share, demand, growth, trends, companies active in the industry and forecasts for the coming years. Growing pet adoption rate coupled with increasing disposable income of pet owners will drive pet cancer therapeutics market growth. Strong and robust drug pipeline for treatment of pet cancer will stimulate business growth over
Rhabdomyosarcoma Market Booming in Healthcare With Eli Lilly & Company, Boehring …
“Global Rhabdomyosarcoma Market” Report of Market Research Future (MRFR)’s Explores Scope of the Study as Research Objective, Assumptions and Limitations in-depth. The report gives Market Dynamics by Major Drivers, Restraints, Opportunities and Challenges. Rhabdomyosarcoma Market - Highlights Rhabdomyosarcoma is anticipated to grow at a CAGR of ~4.8%. Rhabdomyosarcoma or RMS is a type of soft tissue cancer. It is rare cancer and affects the skeletal muscle tissue. Sometimes, it also affects the
Pet Cancer Therapeutics Market 2018-2025 Report With Leading Players, Applicatio …
The latest research report on the Pet Cancer Therapeutics market for the forecast period, 2018 – 2025 is involved in screening the business environment and the companies operating in the Pet Cancer Therapeutics industry. Importantly, the research sheds a lot of light on their winning strategies to help stakeholders, business owners, and field marketing executives stay ahead in the competition. Besides, the industry is thoroughly weighed upon on
Pet Cancer Therapeutics Market Key Player Analysis - Merial, Aratana Therapeutic …
Pet Cancer Therapeutics Market analysis is offered for global market including development trends by regions, competitive analysis of the Pet Cancer Therapeutics Market. Document Readers Industry report concentrates on the main drivers and constraints for the key players. Pet healthcare companies are focusing on development of drugs for mast cell cancer and melanoma among other cancer types. This trend will witness change as medicines to treat lymphoma and mammary cell
Pet Cancer Therapeutics Market Analysis 2018 Eminent Players – Zoetis, Merial, …
Pet Cancer Therapeutics Market size to exceed USD 300 million by 2024, as per a new research report by Global Market Insights, Inc. Growing pet adoption rate coupled with increasing disposable income of pet owners will drive pet cancer therapeutics market growth. Strong and robust drug pipeline for treatment of pet cancer will stimulate business growth over the forecast years. High cost of pet cancer drugs along with rising instances of